交易 Revance The - RVNC CFD
新增到我的最愛- 摘要
- 曆史數據
- 活動
- 盈虧控制
- 資産負債表
- 現金流
交易條件
價差 | 0.05 | ||||||||
多頭倉位隔夜費用
多頭隔夜費用
前往平台 | -0.026179% | ||||||||
空頭倉位隔夜費用
空頭隔夜費用
前往平台 | 0.003957% | ||||||||
隔夜費時間 | 21:00 (UTC) | ||||||||
最小成交量 | 1 | ||||||||
貨幣 | USD | ||||||||
保證金 | 5% | ||||||||
股票交易 | United States of America | ||||||||
交易委員會 | 0% |
*Information provided by Capital.com
Revance Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
“D”分數表示相對 ESG 表現較差,公開報告重要 ESG 數據的透明度不足。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 拋售 | 自訂 | 變化 (%) | 打開 | 最高 | 最小 |
---|---|---|---|---|---|---|
Mar 27, 2024 | 4.91 | 0.20 | 4.25% | 4.71 | 4.93 | 4.65 |
Mar 26, 2024 | 4.67 | 0.00 | 0.00% | 4.67 | 4.84 | 4.61 |
Mar 25, 2024 | 4.62 | -0.28 | -5.71% | 4.90 | 4.98 | 4.55 |
Mar 22, 2024 | 4.84 | -0.24 | -4.72% | 5.08 | 5.10 | 4.84 |
Mar 21, 2024 | 5.16 | 0.11 | 2.18% | 5.05 | 5.40 | 5.05 |
Mar 20, 2024 | 5.05 | 0.19 | 3.91% | 4.86 | 5.09 | 4.74 |
Mar 19, 2024 | 4.90 | 0.00 | 0.00% | 4.90 | 5.14 | 4.84 |
Mar 18, 2024 | 4.91 | -0.32 | -6.12% | 5.23 | 5.23 | 4.86 |
Mar 15, 2024 | 5.28 | -0.15 | -2.76% | 5.43 | 5.49 | 5.28 |
Mar 14, 2024 | 5.40 | -0.55 | -9.24% | 5.95 | 6.01 | 5.38 |
Mar 13, 2024 | 5.98 | -0.21 | -3.39% | 6.19 | 6.34 | 5.94 |
Mar 12, 2024 | 6.26 | 0.12 | 1.95% | 6.14 | 6.31 | 5.88 |
Mar 11, 2024 | 6.24 | 0.05 | 0.81% | 6.19 | 6.43 | 6.08 |
Mar 8, 2024 | 5.99 | -0.23 | -3.70% | 6.22 | 6.37 | 5.81 |
Mar 7, 2024 | 6.13 | -0.21 | -3.31% | 6.34 | 6.39 | 6.10 |
Mar 6, 2024 | 6.30 | -0.33 | -4.98% | 6.63 | 6.68 | 6.16 |
Mar 5, 2024 | 6.46 | 0.38 | 6.25% | 6.08 | 6.68 | 6.01 |
Mar 4, 2024 | 6.06 | -0.04 | -0.66% | 6.10 | 6.37 | 5.79 |
Mar 1, 2024 | 6.93 | -0.46 | -6.22% | 7.39 | 7.53 | 6.93 |
Feb 29, 2024 | 7.12 | 1.13 | 18.86% | 5.99 | 7.43 | 5.76 |
Revance The Events
時間 (UTC) | 國家 | 事件 |
---|---|---|
Thursday, May 2, 2024 | ||
時間 (UTC) 15:00 | 國家 US
| 事件 Revance Therapeutics Inc Annual Shareholders Meeting Revance Therapeutics Inc Annual Shareholders MeetingForecast(預報) -返回 - |
Monday, May 6, 2024 | ||
時間 (UTC) 20:00 | 國家 US
| 事件 Q1 2024 Revance Therapeutics Inc Earnings Release Q1 2024 Revance Therapeutics Inc Earnings ReleaseForecast(預報) -返回 - |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 132.565 | 77.798 | 15.325 | 0.413 | 3.729 |
收入 | 132.565 | 77.798 | 15.325 | 0.413 | 3.729 |
總營業費用 | 474.523 | 352.474 | 288.487 | 164.872 | 146.363 |
銷售/一般/行政費用,總計 | 217.121 | 192.094 | 149.743 | 62.011 | 53.863 |
研究與開發 | 99.639 | 114.484 | 123.724 | 102.861 | 92.5 |
異常費用(收入) | 69.789 | 0 | 0 | ||
營業收入 | -341.958 | -274.676 | -273.162 | -164.459 | -142.634 |
利息收入(費用),非經營淨值 | -11.583 | -5.875 | -10.955 | 5.333 | 3.839 |
其他,淨值 | -2.181 | -0.759 | -0.592 | -0.303 | -0.773 |
稅前淨收入 | -355.722 | -281.31 | -284.709 | -159.429 | -139.568 |
稅後淨收入 | -356.422 | -281.31 | -282.089 | -159.429 | -142.568 |
未計算非常項目前的淨收益 | -356.422 | -281.31 | -282.089 | -159.429 | -142.568 |
淨收入 | -356.422 | -281.31 | -282.089 | -159.429 | -142.568 |
普通股股東可獲收益 (不含非經常性項目) | -356.422 | -281.31 | -282.089 | -159.429 | -142.568 |
普通股股東可獲收益 (含非經常性項目) | -356.422 | -281.31 | -282.089 | -159.429 | -142.568 |
攤薄淨收入 | -356.422 | -281.31 | -282.089 | -159.429 | -142.568 |
攤薄後加權平均股 | 72.7133 | 67.5078 | 58.0092 | 43.4608 | 36.1716 |
扣除特別項目的每股攤薄盈利 | -4.90174 | -4.16707 | -4.86284 | -3.66834 | -3.94144 |
每股正常攤薄盈利 | -4.27788 | -4.16707 | -4.86284 | -3.66834 | -3.94144 |
非常規項目總計 | 0 | ||||
收入成本,共計 | 51.667 | 23.41 | 4.769 | ||
毛利 | 80.898 | 54.388 | 10.556 | ||
Depreciation / Amortization | 36.307 | 22.486 | 10.251 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 58.134 | 49.331 | 49.921 | 29.015 | 28.368 |
收入 | 58.134 | 49.331 | 49.921 | 29.015 | 28.368 |
收入成本,共計 | 21.307 | 16.171 | 23.515 | 10.736 | 9.523 |
毛利 | 36.827 | 33.16 | 26.406 | 18.279 | 18.845 |
總營業費用 | 123.633 | 107.363 | 194.332 | 106.499 | 86.21 |
銷售/一般/行政費用,總計 | 76.344 | 63.869 | 63.545 | 64.093 | 46.186 |
研究與開發 | 22.452 | 20.704 | 19.541 | 26.103 | 24.913 |
Depreciation / Amortization | 3.53 | 6.619 | 17.942 | 5.567 | 5.588 |
營業收入 | -65.499 | -58.032 | -144.411 | -77.484 | -57.842 |
利息收入(費用),非經營淨值 | -1.22 | -1.527 | 0.259 | -6.627 | -3.316 |
其他,淨值 | -0.599 | -0.234 | -1.8 | 0.118 | -0.277 |
稅前淨收入 | -67.318 | -59.793 | -145.952 | -83.993 | -61.435 |
稅後淨收入 | -67.318 | -59.793 | -145.952 | -84.693 | -61.435 |
未計算非常項目前的淨收益 | -67.318 | -59.793 | -145.952 | -84.693 | -61.435 |
淨收入 | -67.318 | -59.793 | -145.952 | -84.693 | -61.435 |
普通股股東可獲收益 (不含非經常性項目) | -67.318 | -59.793 | -145.952 | -84.693 | -61.435 |
普通股股東可獲收益 (含非經常性項目) | -67.318 | -59.793 | -145.952 | -84.693 | -61.435 |
攤薄淨收入 | -67.318 | -59.793 | -145.952 | -84.693 | -61.435 |
攤薄後加權平均股 | 83.6859 | 81.1341 | 80.2079 | 72.2083 | 70.0615 |
扣除特別項目的每股攤薄盈利 | -0.80441 | -0.73696 | -1.81967 | -1.1729 | -0.87687 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.80441 | -0.73696 | -0.94957 | -1.1729 | -0.87687 |
異常費用(收入) | 69.789 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 374.727 | 246.117 | 450.003 | 296.602 | 207.922 |
現金和短期投資 | 340.707 | 225.071 | 436.505 | 290.115 | 175.812 |
現金等價物 | 108.965 | 110.623 | 333.558 | 171.16 | 73.256 |
短期投資 | 231.742 | 114.448 | 102.947 | 118.955 | 102.556 |
應收賬款總額,淨額 | 11.339 | 3.348 | 1.829 | 0 | 27 |
應收賬款 - 貿易,淨額 | 11.339 | 3.348 | 1.829 | 0 | 27 |
預付的費用 | 4.356 | 7.544 | 5.793 | 6.487 | 5.11 |
其他流動資産,總計 | |||||
總資産 | 581.9 | 531.163 | 720.22 | 340.287 | 226.348 |
物業/廠房/設備,總計 - 淨額 | 67.755 | 69.001 | 47.131 | 41.286 | 14.449 |
物業/廠房/設備,總計 - 總額 | 96.347 | 92.33 | 66.622 | 58.152 | 28.421 |
累計折舊,總計 | -28.592 | -23.329 | -19.491 | -16.866 | -13.972 |
長期投資 | |||||
其他長期資産,總計 | 35.239 | 13.747 | 4.779 | 2.399 | 3.977 |
流動負債總額 | 75.682 | 67.289 | 60.964 | 40.979 | 31.97 |
應付賬款 | 4.546 | 10.603 | 12.657 | 8.01 | 8.434 |
預提費用 | 57.037 | 42.862 | 35.903 | 21.9 | 14.407 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
長期債務的當前部分/資本租賃 | 0.669 | 0 | |||
其他流動負債,總計 | 13.43 | 13.824 | 12.404 | 11.069 | 9.129 |
負債總額 | 569.3 | 462.692 | 345.93 | 114.797 | 80.726 |
長期債務總額 | 379.374 | 280.635 | 180.526 | 0 | 0 |
長期債務 | 379.374 | 280.635 | 180.526 | ||
其他負債,總計 | 114.244 | 114.768 | 104.44 | 73.818 | 48.756 |
股權 | 12.6 | 68.471 | 374.29 | 225.49 | 145.622 |
普通股 | 0.082 | 0.072 | 0.069 | 0.052 | 0.037 |
額外實收資本 | 1767.27 | 1466.37 | 1500.51 | 1069.64 | 830.368 |
留存收益(累計赤字) | -1754.37 | -1397.95 | -1126.29 | -844.204 | -684.775 |
其他權益,總計 | -0.374 | -0.018 | 0 | 0.003 | -0.008 |
總負債和股東權益 | 581.9 | 531.163 | 720.22 | 340.287 | 226.348 |
已發行普通股總數 | 82.3858 | 71.5841 | 69.1787 | 52.3747 | 36.9752 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
總庫存 | 18.325 | 10.154 | 5.876 | ||
商譽,淨額 | 77.175 | 146.964 | 146.964 | ||
無形資産,淨額 | 27.004 | 55.334 | 71.343 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 388.519 | 378.947 | 323.024 | 374.727 | 415.594 |
現金和短期投資 | 300.245 | 319.723 | 273.949 | 340.707 | 378.627 |
現金等價物 | 179.319 | 141.235 | 136.678 | 108.965 | 104.491 |
短期投資 | 120.926 | 178.488 | 137.271 | 231.742 | 274.136 |
應收賬款總額,淨額 | 25.414 | 17.043 | 15.373 | 11.339 | 11.732 |
應收賬款 - 貿易,淨額 | 25.414 | 17.043 | 15.373 | 11.339 | 11.732 |
總庫存 | 46.214 | 34.448 | 27.775 | 18.325 | 17.178 |
預付的費用 | 16.371 | 7.458 | 5.652 | 4.356 | 8.057 |
總資産 | 532.487 | 597.535 | 547.801 | 581.9 | 711.591 |
物業/廠房/設備,總計 - 淨額 | 95.198 | 73.588 | 79.662 | 67.755 | 73.22 |
物業/廠房/設備,總計 - 總額 | 102.951 | 96.347 | 100.272 | ||
累計折舊,總計 | -23.289 | -28.592 | -27.052 | ||
商譽,淨額 | 0 | 77.175 | 77.175 | 77.175 | 146.964 |
無形資産,淨額 | 10.507 | 28.461 | 31.223 | 27.004 | 42.866 |
其他長期資産,總計 | 38.263 | 39.364 | 36.717 | 35.239 | 32.947 |
流動負債總額 | 82.158 | 74.079 | 77.985 | 75.682 | 74.732 |
應付賬款 | 4.775 | 8.345 | 12.996 | 4.546 | 0.744 |
預提費用 | 57.317 | 39.481 | 36.711 | 57.037 | 50.395 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 10.206 | 10.748 | 9.667 | 13.43 | 14.197 |
負債總額 | 638.688 | 570.749 | 574.474 | 569.3 | 565.878 |
長期債務總額 | 427.101 | 380.348 | 379.859 | 379.374 | 378.889 |
長期債務 | 427.101 | 380.348 | 379.859 | 379.374 | 378.889 |
其他負債,總計 | 129.429 | 116.322 | 116.63 | 114.244 | 112.257 |
股權 | -106.201 | 26.786 | -26.673 | 12.6 | 145.713 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
普通股 | 0.088 | 0.088 | 0.084 | 0.082 | 0.082 |
額外實收資本 | 1916.39 | 1908.24 | 1787.54 | 1767.27 | 1754.51 |
留存收益(累計赤字) | -2022.66 | -1881.48 | -1814.17 | -1754.37 | -1608.42 |
總負債和股東權益 | 532.487 | 597.535 | 547.801 | 581.9 | 711.591 |
已發行普通股總數 | 87.8133 | 87.95 | 84.0172 | 82.3858 | 82.2869 |
其他權益,總計 | -0.013 | -0.061 | -0.125 | -0.374 | -0.46 |
長期債務的當前部分/資本租賃 | 9.86 | 15.505 | 18.611 | 0.669 | 9.396 |
資本租賃義務 | |||||
其他流動資産,總計 | 0.275 | 0.275 | 0.275 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
淨收入/起跑線 | -356.422 | -281.31 | -282.089 | -159.429 | -142.568 |
經營活動産生的現金 | -193.548 | -221.538 | -178.502 | -106.161 | -104.246 |
經營活動産生的現金 | 33.732 | 19.853 | 10.25 | 2.909 | 1.726 |
非現金物品 | 128.477 | 44.693 | 56.085 | 16.087 | 13.879 |
已付現金利息 | 12.231 | 5.031 | 2.53 | 0 | 0.016 |
營運資金的變化 | 0.665 | -4.774 | 39.972 | 34.272 | 22.717 |
投資活動産生的現金 | -138.798 | -29.665 | 12.131 | -17.592 | -107.026 |
資本支出 | -3.21 | -10.375 | -4.216 | -3.238 | -6.991 |
其他投資現金流量項目,總計 | -135.588 | -19.29 | 16.347 | -14.354 | -100.035 |
融資活動産生的現金 | 331.694 | 29.869 | 331.484 | 221.657 | 1.782 |
融資現金流項目 | -8.193 | -8.525 | -37.666 | -2.12 | -2.578 |
股票的發行(報廢),淨額 | 252.834 | 38.394 | 90.84 | 223.777 | 5.292 |
債務的發行(退還),淨額 | 87.053 | 0 | 278.31 | 0 | -0.932 |
現金淨變化 | -0.652 | -221.334 | 165.113 | 97.904 | -209.49 |
Cash Taxes Paid | 0.7 | 0 | 0.1 | 3 | |
Deferred Taxes | 0 | 0 | -2.72 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -59.793 | -356.422 | -210.47 | -125.777 | -64.342 |
Cash From Operating Activities | -69.5 | -193.548 | -163.366 | -105.495 | -61.27 |
Cash From Operating Activities | 6.618 | 33.732 | 16.266 | 10.827 | 5.376 |
Non-Cash Items | 12.164 | 128.477 | 48.354 | 25.899 | 14.942 |
Changes in Working Capital | -28.489 | 0.665 | -17.516 | -16.444 | -17.246 |
Cash From Investing Activities | 95.316 | -138.798 | -179.758 | -61.313 | 44.568 |
Capital Expenditures | -0.87 | -3.21 | -1.922 | -0.92 | -1.456 |
Other Investing Cash Flow Items, Total | 96.186 | -135.588 | -177.836 | -60.393 | 46.024 |
Cash From Financing Activities | 3.265 | 331.694 | 337.867 | 126.478 | 105.313 |
Financing Cash Flow Items | -3.73 | -8.193 | -5.936 | -3.853 | -1.913 |
Issuance (Retirement) of Stock, Net | 9.481 | 252.834 | 250.653 | 33.941 | 9.076 |
Issuance (Retirement) of Debt, Net | -2.486 | 87.053 | 93.15 | 96.39 | 98.15 |
Net Change in Cash | 29.081 | -0.652 | -5.257 | -40.33 | 88.611 |
Deferred Taxes | 0 |
差價合約交易計算器
計算您的假設損益
交易佣金
0
- 1:1
槓桿
1:1
- 20
- 100
- 500
- 1000
- 10000
交易
交易規模(槓桿 x 投資):
打開
拋售
已賣出 做多
Industry: | Biopharmaceuticals |
1222 Demonbreun Street
Suite 2000
NASHVILLE
TENNESSEE 37203
US
盈虧控制
- Annual
- Quarterly
人們也觀看
還在尋找值得信賴的經紀商?
加入全球 580.000 多名交易者,選擇與 Capital.com 交易